{
  "docId": "019de076-34c7-7046-ba4a-b568cf89a7c9",
  "docSlug": "e7da6c89bd00edfe5ee10f12333167ff",
  "documentTitle": "Erasca | Investor Presentation Deck | 56 slides",
  "authorId": "erasca",
  "authorName": "Erasca",
  "documentKindSlug": "pitchdeck",
  "documentKindLabel": "Pitch deck",
  "sourceTypeSlug": "investor_relations",
  "sourceTypeLabel": "Investor relations",
  "presentationDate": "2023-11-01 00:00:00",
  "orientation": "landscape",
  "aspectRatio": 1.7777778,
  "pageNumber": 27,
  "pageCount": 56,
  "prevPage": 26,
  "nextPage": 28,
  "slideType": "solution",
  "function": "present_solution",
  "density": "balanced",
  "nDataPoints": 0,
  "notes": "The diagram shows the signaling pathway with specific drug targets highlighted.",
  "elementsJson": null,
  "metadataConfidence": 1,
  "imagePath": null,
  "slideHref": "/slides/019de076-34c7-7046-ba4a-b568cf89a7c9/27",
  "deckHref": "/decks/019de076-34c7-7046-ba4a-b568cf89a7c9",
  "deckJsonHref": "/decks/019de076-34c7-7046-ba4a-b568cf89a7c9.json",
  "deckAnchorHref": "/decks/019de076-34c7-7046-ba4a-b568cf89a7c9#slide-27",
  "components": [
    {
      "bbox": {
        "h": 0.755,
        "w": 0.445,
        "x": 0.065,
        "y": 0.145
      },
      "kind": "image",
      "text": "Biological pathway diagram showing EGFR, RAS, RAF, MEK, ERK, and PI3K/AKT signaling, with drug targets Cetuximab, Encorafenib, and ERAS-007 indicated.",
      "attrs": null,
      "subkind": "infographic",
      "toolName": null,
      "toolSlug": null,
      "confidence": null,
      "componentId": "91197885-22f8-4e8c-a0f9-f0a04199bb00",
      "frameworkName": null,
      "frameworkSlug": null
    },
    {
      "bbox": {
        "h": 0.45,
        "w": 0.445,
        "x": 0.518,
        "y": 0.285
      },
      "kind": "list",
      "text": "Combined blockade of ERK plus BRAF/EGFR via treatment with ERAS-007 + encorafenib + cetuximab (EC) could: More effectively inhibit the RAS/MAPK pathway and prevent resistance in EC-naïve BRAFm CRC patients than BRAF/EGFR inhibition alone; Overcome treatment-induced resistance to BRAF/EGFR inhibition in EC-treated BRAFm CRC patients",
      "attrs": null,
      "subkind": "bullet",
      "toolName": null,
      "toolSlug": null,
      "confidence": null,
      "componentId": "7d0877ea-42d4-453f-b10f-312ead236be6",
      "frameworkName": null,
      "frameworkSlug": null
    },
    {
      "bbox": {
        "h": 0.038,
        "w": 0.948,
        "x": 0.026,
        "y": 0.045
      },
      "kind": "title",
      "text": "Scientific rationale: Triple blockade of BRAF, EGFR, and ERK in BRAFm CRC",
      "attrs": null,
      "subkind": "headline",
      "toolName": null,
      "toolSlug": null,
      "confidence": null,
      "componentId": "8a2c477f-de7e-44ab-97b9-35c37e6c6531",
      "frameworkName": null,
      "frameworkSlug": null
    }
  ],
  "metrics": [],
  "tools": [],
  "frameworks": [],
  "arcBeats": [
    {
      "to": 42,
      "from": 16,
      "beatId": "de59f7d9-38c9-46a9-8877-a3655888462f",
      "arcName": "Rags to Riches",
      "arcSlug": "rags-to-riches",
      "beatName": "Erasca's pipeline and clinical data",
      "beatSlug": "rags-to-riches-rising-success",
      "evidence": "Slides 16-42 present Erasca's pipeline and clinical data",
      "position": 2,
      "confidence": 0.8,
      "parentBeatName": "Development",
      "parentBeatSlug": "development"
    }
  ],
  "loops": [],
  "imagePathAlt": null,
  "thumbSrc": null,
  "thumbSrcAlt": null,
  "locked": true
}